2月7日,成都生物医药企业康诺亚(HK02162,股价31.60港元,市值88.4亿港元)公告,公司自主研发的1类新药康悦(司普奇拜单抗注射液)获国家药品监督管理局批准上市,用于治疗季节性过敏性鼻炎(SAR)。 这是该药物继2024年9月、12月批准用于治疗成人中重度特应性皮炎、慢性鼻窦炎伴鼻息肉之后获批的第三个适应症。该产品也是全球首个获批治疗季节性过敏性鼻炎的IL-4Rα生物制剂。 从全球...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.